PCRX 250117 15.00C (PCRX250117C15000) Stock Options, News & Quotes

7.20
+0.40+5.88%

15min DelayClose Jan 17 16:00 ET

7.25High6.75Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Value investorr

Aug 23, 2024 11:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19, 2024 10:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

Mr Long Term

Aug 13, 2024 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Value investorr

Aug 12, 2024 09:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...

Shroomie

Aug 9, 2024 15:03

pew pew.. in and out in 30 seconds

$Pacira BioSciences (PCRX.US)$

Share Your Profit/Loss